AIM ImmunoTech Inc. AIM

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
38/100
Developing

Ranked against 712 peers in Biotechnology

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species … Full AIM analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 95.0th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.83), suggesting sticky customer base.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 12.2th percentile with high volatility suggests weak pricing power or commoditized products.
  • Below-Peer Operating Efficiency Operating margin at 14.5th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
21
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where AIM ranks in Biotechnology

AIM ImmunoTech Inc. ranks #389 of 713 scored companies in Biotechnology by moat score — the top 55%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
385 Lipocine Inc. LPCN 38/100 Developing
386 Acumen Pharmaceuticals, Inc. ABOS 38/100 Developing
387 Replimune Group, Inc. REPL 38/100 Developing
388 Tectonic Therapeutic, Inc. TECX 38/100 Developing
389 AIM ImmunoTech Inc. AIM 38/100 Developing
390 Xenon Pharmaceuticals Inc. XENE 38/100 Developing
391 Aptorum Group Limited APM 38/100 Developing
392 Dogwood Therapeutics, Inc. DWTX 38/100 Developing
393 Jaguar Health, Inc. JAGX 38/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How AIM scores on the Corporate Default defenses

Pricing Power

Score 21 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 11 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 41 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 75 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 38 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 40 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding AIM's moat

What is AIM ImmunoTech Inc.'s moat score?

AIM ImmunoTech Inc. (AIM) scores 38 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #389 of 713 scored companies in Biotechnology, the top 55%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (75/100) and its weakest is Cost Advantage (11/100).

How does AIM ImmunoTech Inc. compare with other Biotechnology companies?

AIM ImmunoTech Inc. ranks #389 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Tectonic Therapeutic, Inc. (TECX) at 38 just above it and Xenon Pharmaceuticals Inc. (XENE) at 38 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is AIM ImmunoTech Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for AIM ImmunoTech Inc.?

The Corporate Default template measures 6 defenses, and AIM scores: Pricing Power (21), Cost Advantage (11), Customer Stickiness (41), Capital Efficiency (75), Resilience (38), Scale & Market Position (40). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000